Overview

Versartis International Trial in Adults With Long-Acting Growth Hormone

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.
Phase:
Phase 2
Details
Lead Sponsor:
Versartis Inc.
Collaborator:
Premier Research Group plc
Treatments:
Hormones